Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jun 17, 2020 10:54am
97 Views
Post# 31159990

I think, we need to give them little more time

I think, we need to give them little more time
  1. I like what Sunnybrook is doing, they have resources and trusted name to move forward
It has made progress in the following three areas of research: virus transmission, medical countermeasures including potential antivirals and vaccines, and virus genomics.
  1. I also like the idea and progress by Sinai
The research team at the Lunenfeld-Tanenbaum Research Institute (LTRI) – Mt. Sinai Hospital is exploring the potential of a robotized platform that may be able to monitor the immune response to a COVID-19 infection and assess:
  • Which individuals have been previously exposed to the virus
  • What type and quantity of antibodies have been produced in those individuals
  • How long will any potential immunity persists
  1. Profit Sharing Agreement and PCL Approval
PCL application for EUA has been submitted to the US FDA and PCL is corresponding with an assigned reviewer. I think it will get approval sooner than later. I do not see why it does not get approval as it is already approved in EU and Australia. I know waiting is hard, but we don’t have much of choice. I think they will apply in Canada once they get approval from US FDA.  It will be easy to get approval in Canada once they are approved in USA.
I see only two options for me hold and wait as more progress they make prices eventually start moving upward or I can sell and move on to something else. I think they were expecting approval before this update webinar otherwise they could have waited for another week or two. These things take time and you cannot make it fast with GOVT especially getting approval from FDA.

<< Previous
Bullboard Posts
Next >>